Trials / Completed
CompletedNCT02518529
Study to Assess Tolerability and Safety and Antibody Response to G17DT in Gastric Cancer Patients
An Open, Multi-centre Study to Determine the Tolerability, Safety and Antibody Response Resulting From G17DT at 250mcg at Weeks 0, 2 and 6 With a Booster of 125mcg or 250mcg Given to Patients With Stage I - III Gastric Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Cancer Advances Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Open-label, multicenter study to assess 250µg/0.2ml G17DT injection at weeks 0, 2 and 6. At or after week 20 and up to and including week 44. Subjects who raised antibodies to G17DT were given an additional dose of 125µg/0.1ml or 250µg/0.2ml G17DT between weeks 20-44 (study duration 52 weeks).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | G17DT |
Timeline
- Start date
- 2001-02-01
- Primary completion
- 2002-12-01
- Completion
- 2002-12-01
- First posted
- 2015-08-10
- Last updated
- 2015-08-10
Source: ClinicalTrials.gov record NCT02518529. Inclusion in this directory is not an endorsement.